Welcome to our dedicated page for Lifestance Health Group SEC filings (Ticker: LFST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for LifeStance Health Group, Inc. (Nasdaq: LFST), a mental healthcare company focused on outpatient services. As a public company with common stock registered on The Nasdaq Stock Market LLC, LifeStance files documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.
LifeStance’s filings offer detailed information about its business as one of the nation’s largest providers of virtual and in-person outpatient mental healthcare. In these documents, the company describes its operations, risk factors, financial condition and results of operations. For example, current reports on Form 8-K have been used to furnish earnings press releases for specific quarters and to disclose changes in the board of directors, including director resignations and appointments with related equity awards under the company’s equity incentive plan.
Investors can review LifeStance’s discussion of non-GAAP financial measures such as Center Margin and Adjusted EBITDA, along with reconciliations to comparable GAAP measures, within its filings and related exhibits. The company also outlines forward-looking statements and associated risks, referring readers to the "Risk Factors" section of its Form 10-K and subsequent filings for more comprehensive risk disclosures.
On Stock Titan, LifeStance filings are updated as new documents are made available through the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy filings, highlight significant changes from prior periods and clarify technical language. Users can quickly identify items related to quarterly and annual results, governance events reported on Form 8-K and other regulatory disclosures relevant to LFST, while still having access to the full original documents for detailed review.
LifeStance Health Group director Kenneth A. Burdick reported compensation-related stock movements on
To cover tax withholding obligations on these RSUs and PSUs, the issuer withheld 327,209 shares at
LifeStance Health Group, Inc. Chief Executive Officer David Bourdon reported stock-based compensation activity rather than open-market trading. On March 9, 2026, previously granted restricted stock units (RSUs) and performance-based restricted stock units (PSUs) vested, resulting in share awards recorded as acquisitions.
To cover tax withholding obligations tied to the vesting and net settlement of these RSUs and PSUs, the company withheld a total of 148,382 shares at a reported price of
LifeStance Health Group, Inc. Chief Operating Officer Lisa K. Miller reported equity compensation activity involving restricted stock units and related tax withholding. On March 9, 2026, she acquired 26,836 shares of common stock at a stated price of $0.00 per share in a grant/award tied to vested performance-based restricted stock units previously granted on March 6, 2025.
On the same date, the issuer withheld 14,766 shares of common stock at $6.91 per share to satisfy tax obligations for vested RSUs and separately withheld 13,446 shares at $6.91 per share for tax obligations related to vested PSUs. Footnotes specify these withheld shares reduce the shares issued to Miller and do not constitute any open-market sale. After these transactions, she directly owned 329,201 shares of common stock.
LifeStance Health Group Chief People Officer Ann Varanakis reported compensation-related share activity in connection with vested restricted stock units (RSUs) and performance-based RSUs (PSUs) on March 9, 2026.
She acquired 26,836 and 59,789 shares of common stock at $0.00 per share through RSU and PSU settlements. To cover tax withholding obligations on these vestings, the issuer withheld a total of 44,963 shares at a reference price of $6.91 per share. The footnotes state these withholdings reduce shares delivered and do not involve any open-market sales. Following these transactions, Varanakis directly holds 422,037 shares of LifeStance common stock.
LifeStance Health Group director and officer Ryan Pardo reported equity compensation vesting and related tax withholding transactions in Common Stock. On March 9, 2026, he received stock awards of 40,254 and 105,711 shares at no cost as restricted and performance-based units vested.
To cover tax obligations on these vestings, the issuer withheld 12,280, 15,841, and 38,479 shares at $6.91 per share, which the footnotes state are not open-market sales. Following these transactions, Pardo directly owned 1,102,742 shares and had indirect exposure to 2,551,520 shares held by the Kimberly Pardo Irrevocable Trust, where he disclaims beneficial ownership beyond any pecuniary interest.
LifeStance Health Group, Inc. executive Ryan McGroarty reported equity compensation activity involving performance-based restricted stock units (PSUs) that vested on March 9, 2026. He acquired 127,878 shares of common stock from PSUs granted on March 17, 2025, and 65,168 shares from PSUs granted on March 24, 2025.
To cover tax withholding obligations on these PSU settlements, the issuer withheld 50,929 shares and 25,644 shares at a price of $6.91 per share. The footnotes state these withholdings reduced the shares delivered on vesting and did not involve any open-market sales.
After these transactions, McGroarty directly held 844,084 shares of LifeStance common stock.
LifeStance Health Group, Inc. Chief Technology Officer Vukasin Paunovich reported equity compensation activity tied to performance-based restricted stock units. On
LifeStance Health Group, Inc. appointed Lisa Miller as its Chief Operating Officer and Principal Operating Officer effective March 10, 2026. She has led practice operations at LifeStance since 2022 and previously served in senior operating roles at Invo Healthcare.
In her new role, Ms. Miller will receive an annual base salary of $485,000 and, beginning in calendar year 2026, will be eligible for an annual target bonus equal to 85% of base salary, based on performance. She will also receive annual equity awards under the 2021 Equity Incentive Plan with a current aggregate target grant date value of about $1,500,000 in time-based and performance-based restricted stock units vesting over three years, generally subject to continued employment and achievement of performance targets.
LifeStance Health Group, Inc. reported that Chief Medical Officer Stephanie Carin Eken acquired equity-based compensation in the form of restricted stock units. On March 5, 2026, she was granted 115,107 RSUs, each representing a contingent right to receive one share of LifeStance common stock.
The Form 4 classifies this as a grant or award acquisition at a price of $0.00 per share, typical for stock-based compensation. Following this grant, her directly held common stock and RSU-related interest totals 115,107 shares of LifeStance common stock on a contingent basis.
LifeStance Health Group, Inc. officer Ryan Pardo reported equity award activity in the company’s common stock. On March 5, 2026, he acquired 129,496 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock.
On March 6, 2026, 21,854 shares were withheld at $6.93 per share to cover tax obligations related to vested RSUs. The filing specifies that these withheld shares reduce the shares issued to him and do not constitute any open‑market sale.
After these transactions, he held 1,023,377 shares directly and 2,551,520 shares indirectly through the Kimberly Pardo Irrevocable Trust, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.